References
- LaneDPCancer. p53, guardian of the genomeNature1992358638115161614522
- KleinCVassilevLTTargeting the p53-MDM2 interaction to treat cancerBr J Cancer20049181415141915452548
- MullerPAVousdenKHp53 mutations in cancerNat Cell Biol20131512823263379
- BiegingKTMelloSSAttardiLDUnravelling mechanisms of p53-mediated tumour suppressionNat Rev Cancer201414535937024739573
- LevineAJp53, the cellular gatekeeper for growth and divisionCell19978833233319039259
- VousdenKHLaneDPp53 in health and diseaseNat Rev Mol Cell Biol20078427528317380161
- BroshRRotterVWhen mutants gain new powers: news from the mutant p53 fieldNat Rev Cancer200991070171319693097
- VaughanCPearsallIYeudallADebSPDebSp53: its mutations and their impact on transcriptionSubcell Biochem201485719025201189
- MomandJZambettiGPMdm-2: “big brother” of p53J Cell Biochem19976433433529057092
- MichaelDOrenMThe p53 and Mdm2 families in cancerCurr Opin Genet Dev2002121535911790555
- ManfrediJJThe Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressorGenes Dev201024151580158920679392
- ShangarySWangSSmall-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapyAnnu Rev Pharmacol Toxicol20094922324118834305
- LahavGRosenfeldNSigalADynamics of the p53-Mdm2 feedback loop in individual cellsNat Genet200436214715014730303
- BaiLWangSTargeting apoptosis pathways for new cancer therapeuticsAnnu Rev Med20146513915524188661
- SelivanovaGTherapeutic targeting of p53 by small moleculesSemin Cancer Biol2010201465620206268
- SteghAHTargeting the p53 signaling pathway in cancer therapy – the promises, challenges and perilsExpert Opin Ther Targets2012161678322239435
- EssmannFSchulze-OsthoffKTranslational approaches targeting the p53 pathway for anti-cancer therapyBr J Pharmacol2012165232834421718309
- KussiePHGorinaSMarechalVStructure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domainScience199627452899489538875929
- Estrada-OrtizNNeochoritisCGDömlingAHow to design a successful p53-MDM2/X interaction inhibitor: a thorough overview based on crystal structuresChemMedChem201611875777226676832
- VassilevLTVuBTGravesBIn vivo activation of the p53 pathway by small-molecule antagonists of MDM2Science2004303565984484814704432
- PopowiczGMCzarnaAWolfSStructures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discoveryCell Cycle2010961104111120237429
- MiyazakiMNaitoHSugimotoYSynthesis and evaluation of novel orally active p53-MDM2 interaction inhibitorsBioorg Med Chem201321144319433123685175
- HuangYWolfSKoesDExhaustive fluorine scanning toward potent p53-Mdm2 antagonistsChemMedChem201271495221954050
- Gonzalez-Lopez de TurisoFSunDRewYRational design and binding mode duality of MDM2-p53 inhibitorsJ Med Chem201356104053407023597064
- DingQZhangZLiuJJDiscovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical developmentJ Med Chem201356145979598323808545
- GessierFKallenJJacobyEDiscovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding modeBioorg Med Chem Lett201525173621362526141769
- YuMWangYZhuJDiscovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 InteractionACS Med Chem Lett20145889489925147610
- GonzalezAZEksterowiczJBartbergerMDSelective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interactionJ Med Chem20145762472248824548297
- YuZZhuangCWuYDesign, synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitorsInt J Mol Sci2014159157411575325198897
- AllenJGBourbeauMPWohlhieterGEDiscovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interactionJ Med Chem200952227044705319856920
- Chemical Computing Group IncMolecular Operating Environment (MOE, version 2013-08) Chemical Computing Group Inc.1010 Sher-booke St. West, Suite #910, Montreal, QC, Canada H3A 2R7, 2015
- HalgrenTAMerck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rulesJ Comput Chem1996175–6616641
- VeberDFJohnsonSRChengHYSmithBRWardKWKoppleKDMolecular properties that influence the oral bioavailability of drug candidatesJ Med Chem200245122615262312036371
- LipinskiCALombardoFDominyBWFeeneyPJExperimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdv Drug Deliv Rev2001461–332611259830
- FriesnerRABanksJLMurphyRBGLIDE: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracyJ Med Chem20044771739174915027865
- ISO – International Organization for StandardizationISO 10993-5– Biological Evaluation of Medical Devices. Part 5: Testes for In Vitro Cytotoxicity3rd edGenevaISO2009
- GhattasMAAtatrehNBichenkovaEVBryceRAProtein tyrosine phosphatases: ligand interaction analysis and optimisation of virtual screeningJ Mol Graph Model20145211412325038507
- GhattasMAMansourRAAtatrehNBryceRAAnalysis of Enoyl-Acyl carrier protein reductase structure and interactions yields an efficient virtual screening approach and suggests a potential allosteric siteChem Biol Drug Des201687113114226259619
- ZacheNLambertJMRökaeusNMutant p53 targeting by the low molecular weight compound STIMA-1Mol Oncol200821708019383329
- GudasJMNguyenHKleinRCKatayoseDSethPCowanKHDifferential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cellsClin Cancer Res19951171809815889
- KimKBurghardtRBarhoumiRLeeSOLiuXSafeSMDM2 regulates estrogen receptor α and estrogen responsiveness in breast cancer cellsJ Mol Endocrinol2011462677921169420